531210 Stock Overview
Colinz Laboratories Limited manufactures and markets pharmaceutical formulations in India.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Colinz Laboratories Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹41.20 |
| 52 Week High | ₹46.90 |
| 52 Week Low | ₹33.35 |
| Beta | 0.40 |
| 1 Month Change | 7.91% |
| 3 Month Change | 5.10% |
| 1 Year Change | -1.34% |
| 3 Year Change | 233.60% |
| 5 Year Change | 504.99% |
| Change since IPO | 381.87% |
Recent News & Updates
Recent updates
Shareholder Returns
| 531210 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 5.6% | 1.4% | 2.8% |
| 1Y | -1.3% | 57.2% | 46.6% |
Return vs Industry: 531210 underperformed the Indian Pharmaceuticals industry which returned 57.2% over the past year.
Return vs Market: 531210 underperformed the Indian Market which returned 46.6% over the past year.
Price Volatility
| 531210 volatility | |
|---|---|
| 531210 Average Weekly Movement | 7.3% |
| Pharmaceuticals Industry Average Movement | 5.9% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in IN Market | 10.1% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: 531210 has not had significant price volatility in the past 3 months.
Volatility Over Time: 531210's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1986 | 67 | N. Menon | www.colinz.com |
Colinz Laboratories Limited manufactures and markets pharmaceutical formulations in India. The company provides pharmaceutical formulations in the dosage forms of tablets, capsules, granules, liquid orals, ointments, injectables, creams, etc.; and specialized products for gynecology, cardiology, gastroenterology, etc. Its allopathy products include oncology products, such as imitinib, erlotinib, letrozole, exemestane, bortezomib, fludarabine phosphate, doxorubicin, filgrastim, pegylated liposome doxorubicin etc.; antiritrovirals, including lopinavir, indinavir, ritonavir, darunavir, zidovudine, lamivudin, and various combination therapy products; and products for other therapeutic areas, such as antibiotics, anti-pyretics, anti-fungals, anti-malarials, anti-virals, anti-manics, anti-convulsants, anti-migraines, anti-allergics, anti-diarrhoeals, anti-inflammatory, anti-piles, anthelmintics, anti-emetics, anti-spasmodics, sedatives, cerebral activators, ulcer healing agents, laxatives, probiotics, digestive enzymes, topical steroids, ear/eye drops, hormone, sunscreens and vitamins, etc., as well as drugs used in protozoal infestations and neuropathy. The company’s ayurvedic products consists of anti-diarrhoeals, anti-pyretics, anti-inflammatories, anti-spasmodics, cough syrups, apetite stimulating agents, memory boosters, anti-piles, antacids, liver tonics, ulcer healing agents, digestive agents, ear drops, uterine tonics, anti-diabetics, and general tonics, as well as drugs to treat oligospermia and erectile dysfunction.
Colinz Laboratories Limited Fundamentals Summary
| 531210 fundamental statistics | |
|---|---|
| Market cap | ₹103.79m |
| Earnings (TTM) | ₹4.79m |
| Revenue (TTM) | ₹71.21m |
21.7x
P/E Ratio1.5x
P/S RatioIs 531210 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 531210 income statement (TTM) | |
|---|---|
| Revenue | ₹71.21m |
| Cost of Revenue | ₹23.85m |
| Gross Profit | ₹47.36m |
| Other Expenses | ₹42.58m |
| Earnings | ₹4.79m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.90 |
| Gross Margin | 66.51% |
| Net Profit Margin | 6.72% |
| Debt/Equity Ratio | 5.4% |
How did 531210 perform over the long term?
See historical performance and comparison